-
1.发明公开HYALURONIC ACID MODIFICATION PRODUCTS AND DRUG CARRIERS USING THEM 有权HYALUORNSÄURE-MODIFIZIERUNGSPRODUKTE UNDARZNEISTOFFTRÄGERDAMIT
公开(公告)号：EP1666518A4
公开(公告)日：2006-11-29
申请号：EP04787709
申请日：2004-09-08
发明人： HIRAKURA TAI , NAKAMURA TERUO , SHIMOBOJI TSUYOSHI
CPC分类号： A61K9/5153 , A61K9/5161 , C08B37/0072 , C08G63/912
摘要： There is provided a drug carrier which has solved the problems of conventional drug carriers, which can encapsulate a low molecular drug efficiently, which can control a sustained release period for a long term, which can control blood residence, which has high dispersibility in an aqueous solution, and which is not problematical in safety. A drug carrier, which comprises injectable fine particles minimal in agglomeration between the particles, and which has excellent biocompatibility, is also provided. A hyaluronic acid modification product comprising hyaluronic acid or its derivative, and a polymer bonded together, the polymer being selected from polylactic acid, polyglycolic acid and lactic acid-glycolic acid copolymer, according to the present invention, provides a drug carrier which encapsulates a low molecular drug efficiently, which can control a sustained release period for a long term, which can control blood residence, which is well dispersible in an aqueous solution, and which is not problematical in safety. The hyaluronic acid modification product of the present invention also provides a drug carrier comprising injectable fine particles minimal in agglomeration between the particles, and having excellent biocompatibility.
摘要翻译： 解决了能够有效地密封低分子药物的常规药物载体的问题的药物载体，该药物载体实现长期控制缓释期和控制血液中滞留，在水溶液中的分散性和姿势 在安全方面没有问题; 以及由粒间团聚趋势低的可注射微粒组成的生物相容性优异的药物载体。 这种药物载体可以有效地密封低分子药物，该药物载体可以实现持续释放期的长期控制和血液中滞留的控制，在水溶液中的分散性优异并且在安全性方面没有问题 通过使用包含透明质酸或其衍生物以及与之结合的选自聚乳酸，聚乙醇酸和乳酸/乙醇酸共聚物的聚合物的透明质酸改性产品来提供。 此外，通过使用透明质酸改性产物，也可以提供上述由颗粒间聚集倾向低的可注射微粒组成的生物相容性优异的药物载体。
-
公开(公告)号：EP1564220A4
公开(公告)日：2010-03-17
申请号：EP03774146
申请日：2003-11-21
CPC分类号： A61K9/06 , A61K9/0019 , A61K47/36 , C08B37/0072
-
公开(公告)号：EP1333036A4
公开(公告)日：2004-09-29
申请号：EP01970285
申请日：2001-09-28
CPC分类号： C07K14/505 , A61K38/1816 , A61K47/60
摘要： A polyethylene glycol-modified erythropoietin (PEG-modified EPO) obtained by chemically modifying the lysine residue at the 52-position of natural erythropoietin (natural EPO) with polyethylene glycol. To enhance the long-lasting drug effect of EPO without damaging the physiological activity of EPO which is a sugar chain-rich glycoprotein, it has been required to develop a PEG-modified EPO having an extremely high long-lasting drug effect by introducing PEG into a controlled binding site at a controlled number of binding molecules. The above-described PEG-modified EPO shows a high long-lasting drug effect, thereby solving these problems.
-
公开(公告)号：EP1790665A4
公开(公告)日：2012-10-10
申请号：EP05782114
申请日：2005-09-07
发明人： YASUGI KENJI , NAKAMURA TERUO , SHIMOBOJI T , SATO MIKA
CPC分类号： C08B37/0072 , A61K47/61 , C08J3/075 , C08J3/122 , C08L5/08
-
公开(公告)号：EP1477496A4
公开(公告)日：2006-08-02
申请号：EP03734634
申请日：2003-02-03
发明人： SEKIMORI YASUO , NAKAMURA TERUO , SHIMIZU MASARU
IPC分类号： A61K38/29 , A61K47/48 , A61P19/00 , C07K14/635 , C07K14/435 , A61K38/22 , A61K47/34
CPC分类号： C07K14/635 , A61K38/29 , A61K47/60
摘要： It is intended to provide PTH or a PTH derivative showing an improved bioavailability and little side effects without worsening the PTH activity. By binding PEG to PTH or a PTH derivative, the bioavailability can be improved and side effects can be relieved while sustaining the PTH activity.
-
-
-
-
搜索结果
5 条记录 (耗时 0.009 秒)
